富衛香港:上半年新業務保單數目增34% 第三季增長動力持續
富衛香港及澳門首席產品總監余(柏)堅表示,富衛上半年新業務保單數目按年增加34%,較2019年疫情前增長61%。受惠新產品帶動內地客銷售,預期第三季增長動力持續強勁。
他提到,富衛香港去年的理賠統計顯示,2022年身故和危疾賠償金額較2019年疫情前分別提升113%和40%,癌症則繼續成為身故和危疾賠償的第一大成因。
該報告亦顯示,去年危疾賠償個案中超過一半的被保人為39歲或以下,反映危疾年輕化。有見及此,富衛推出「危疾緻尚保」系列,提供涵蓋家庭三代,並為夾世代應對未來可能發生之長者疾病的危疾保障及支援服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.